Trial Profile
Safety and efficacy of bortezomib and dexamethasone followed by risk adapated high dose melphalan and autologous stem cell transplantation in patients with light chain amyloidosis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 20 Jan 2016
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Bortezomib (Primary) ; Dexamethasone; Dexamethasone; Melphalan
- Indications Amyloid light-chain amyloidosis
- Focus Adverse reactions; Therapeutic Use
- 20 Jan 2016 New trial record
- 08 Dec 2015 Results presented at the 57th Annual Meeting and Exposition of the American Society of Hematology